TR
T. Rowe Price Investment Management, Inc. disclosed a 9.6% stake in PCVX
T. Rowe Price Investment Management, Inc. reported owning 9.6% of Vaxcyte, Inc. (PCVX) (14,312,368 shares) in a Schedule 13G filed Nov 6, 2026.
A 13G is a passive stake: the holder does not plan to push for changes.